BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 25937048)

  • 1. ROR1-targeted delivery of OSU-2S, a nonimmunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle-cell lymphoma in vitro and in vivo.
    Mani R; Chiang CL; Frissora FW; Yan R; Mo X; Baskar S; Rader C; Klisovic R; Phelps MA; Chen CS; Lee RJ; Byrd JC; Baiocchi R; Lee LJ; Muthusamy N
    Exp Hematol; 2015 Sep; 43(9):770-4.e2. PubMed ID: 25937048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia.
    Mani R; Mao Y; Frissora FW; Chiang CL; Wang J; Zhao Y; Wu Y; Yu B; Yan R; Mo X; Yu L; Flynn J; Jones J; Andritsos L; Baskar S; Rader C; Phelps MA; Chen CS; Lee RJ; Byrd JC; Lee LJ; Muthusamy N
    Leukemia; 2015 Feb; 29(2):346-55. PubMed ID: 24947019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death.
    Alinari L; Mahoney E; Patton J; Zhang X; Huynh L; Earl CT; Mani R; Mao Y; Yu B; Quinion C; Towns WH; Chen CS; Goldenberg DM; Blum KA; Byrd JC; Muthusamy N; Praetorius-Ibba M; Baiocchi RA
    Blood; 2011 Dec; 118(26):6893-903. PubMed ID: 22042694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma.
    Omar HA; Chou CC; Berman-Booty LD; Ma Y; Hung JH; Wang D; Kogure T; Patel T; Terracciano L; Muthusamy N; Byrd JC; Kulp SK; Chen CS
    Hepatology; 2011 Jun; 53(6):1943-58. PubMed ID: 21391227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-immunosuppressive FTY720-derivative OSU-2S mediates reactive oxygen species-mediated cytotoxicity in canine B-cell lymphoma.
    Mani R; Yan R; Mo X; Chen CS; Phelps MA; Klisovic R; Byrd JC; Kisseberth WC; London CA; Muthusamy N
    Vet Comp Oncol; 2017 Sep; 15(3):1115-1118. PubMed ID: 27136276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FTY720-induced blockage of autophagy enhances anticancer efficacy of milatuzumab in mantle cell lymphoma: is FTY720 the next autophagy-blocking agent in lymphoma treatment?
    Alinari L; Baiocchi RA; Praetorius-Ibba M
    Autophagy; 2012 Mar; 8(3):416-7. PubMed ID: 22377620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas.
    Gupta P; Goldenberg DM; Rossi EA; Cardillo TM; Byrd JC; Muthusamy N; Furman RR; Chang CH
    Blood; 2012 Apr; 119(16):3767-78. PubMed ID: 22271448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ROR1 targeted immunoliposomal delivery of OSU-2S shows selective cytotoxicity in t(1;19)(q23;p13) translocated B-cell acute lymphoblastic leukemia.
    Goswami S; Chiang CL; Zapolnik K; Nunes J; Ventura A; Mo X; Xie Z; Lee LJ; Baskar S; Rader C; Byrd JC; Phelps M; Bhatnagar B; Muthusamy N
    Leuk Res; 2022 Jul; 118():106872. PubMed ID: 35640397
    [No Abstract]   [Full Text] [Related]  

  • 9. FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma.
    Liu Q; Alinari L; Chen CS; Yan F; Dalton JT; Lapalombella R; Zhang X; Mani R; Lin T; Byrd JC; Baiocchi RA; Muthusamy N
    Clin Cancer Res; 2010 Jun; 16(12):3182-92. PubMed ID: 20460491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma.
    Alinari L; Yu B; Christian BA; Yan F; Shin J; Lapalombella R; Hertlein E; Lustberg ME; Quinion C; Zhang X; Lozanski G; Muthusamy N; Prætorius-Ibba M; O'Connor OA; Goldenberg DM; Byrd JC; Blum KA; Baiocchi RA
    Blood; 2011 Apr; 117(17):4530-41. PubMed ID: 21228331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma.
    Jiang VC; Liu Y; Jordan A; McIntosh J; Li Y; Che Y; Jessen KA; Lannutti BJ; Wang M
    J Hematol Oncol; 2021 Aug; 14(1):132. PubMed ID: 34454548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutting Edge: ROR1/CD19 Receptor Complex Promotes Growth of Mantle Cell Lymphoma Cells Independently of the B Cell Receptor-BTK Signaling Pathway.
    Zhang Q; Wang HY; Liu X; Nunez-Cruz S; Jillab M; Melnikov O; Nath K; Glickson J; Wasik MA
    J Immunol; 2019 Oct; 203(8):2043-2048. PubMed ID: 31534006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantification of OSU-2S, a novel derivative of FTY720, in mouse plasma by liquid chromatography-tandem mass spectrometry.
    Mao Y; Wang J; Zhao Y; Yan R; Li H; Chen CS; Lee RJ; Byrd JC; Lee LJ; Muthusamy N; Phelps MA
    J Pharm Biomed Anal; 2014 Sep; 98():160-5. PubMed ID: 24927402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and Tolerability of the Novel Non-immunosuppressive Fingolimod Derivative, OSU-2S, in Dogs and Comparisons with Data in Mice and Rats.
    Xie Z; Chen M; Goswami S; Mani R; Wang D; Kulp SK; Coss CC; Schaaf LJ; Cui F; Byrd JC; Jennings RN; Schober KK; Freed C; Lewis S; Malbrue R; Muthusamy N; Bennett C; Kisseberth WC; Phelps MA
    AAPS J; 2020 Jul; 22(4):92. PubMed ID: 32676788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting malignant B cells with an immunotoxin against ROR1.
    Baskar S; Wiestner A; Wilson WH; Pastan I; Rader C
    MAbs; 2012; 4(3):349-61. PubMed ID: 22531447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies.
    Mao Y; Triantafillou G; Hertlein E; Towns W; Stefanovski M; Mo X; Jarjoura D; Phelps M; Marcucci G; Lee LJ; Goldenberg DM; Lee RJ; Byrd JC; Muthusamy N
    Clin Cancer Res; 2013 Jan; 19(2):347-56. PubMed ID: 23209030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers.
    Govindan SV; Cardillo TM; Sharkey RM; Tat F; Gold DV; Goldenberg DM
    Mol Cancer Ther; 2013 Jun; 12(6):968-78. PubMed ID: 23427296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models.
    Chan WK; Williams J; Sorathia K; Pray B; Abusaleh K; Bian Z; Sharma A; Hout I; Nishat S; Hanel W; Sloan SL; Yasin A; Denlinger N; Zhang X; Muthusamy N; Vasu S; de Lima M; Yang Y; Baiocchi R; Alinari L
    Exp Hematol Oncol; 2023 Sep; 12(1):79. PubMed ID: 37740214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ROR1 expression is not a unique marker of CLL.
    Barna G; Mihalik R; Timár B; Tömböl J; Csende Z; Sebestyén A; Bödör C; Csernus B; Reiniger L; Peták I; Matolcsy A
    Hematol Oncol; 2011 Mar; 29(1):17-21. PubMed ID: 20597086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ROR1 antibody-drug conjugate huXBR1-402-G5-PNU effectively targets ROR1+ leukemia.
    Hu EY; Do P; Goswami S; Nunes J; Chiang CL; Elgamal S; Ventura AM; Cheney C; Zapolnik K; Williams E; Mani R; Frissora F; Mo X; Waldmeier L; Beerli RR; Peng H; Rader C; Long M; Grawunder U; Byrd JC; Muthusamy N
    Blood Adv; 2021 Aug; 5(16):3152-3162. PubMed ID: 34424320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.